채혈 시장 : 제품 유형, 기술, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Blood Collection Market is projected to grow by USD 22.05 billion at a CAGR of 7.15% by 2032.

Blood Collection Market Introduction

Blood collection is a core enabler of transfusion medicine, diagnostic testing, plasma fractionation, emergency care, and chronic disease management. The market spans venous and capillary blood collection devices, blood bags, evacuated tubes, needles, lancets, safety sets, plasma collection systems, and preanalytical workflow solutions used across hospitals, diagnostic laboratories, blood banks, mobile collection units, and ambulatory care settings.

Demand is supported by the rising burden of cancer, cardiovascular disease, kidney disease, trauma care, maternal health needs, infectious disease surveillance, and routine laboratory testing. Verified public health guidance from the WHO, FDA, CDC, ISO, CLSI, and national blood services continues to shape procurement priorities around sterility, traceability, donor safety, hemolysis reduction, specimen integrity, occupational exposure prevention, and transfusion-transmitted infection control.

Transformative Shifts in the Blood Collection Landscape

The blood collection landscape is shifting from volume-based procurement toward safety, automation, and data-connected workflows. Healthcare providers are prioritizing closed systems, needle safety, single-use sterile consumables, barcode-based traceability, standardized tube handling, and validated preanalytical processes to reduce specimen rejection, occupational exposure, contamination risk, and transfusion-related errors.

Another transformative shift is the expansion of decentralized and patient-centered collection. Capillary blood collection, home-based sampling models, mobile donation drives, and point-of-care testing are changing how samples and blood products enter the healthcare system. Manufacturers that combine ergonomic design, regulatory compliance, automation readiness, sustainable packaging, and digital inventory visibility are gaining strategic relevance in blood collection procurement.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing blood collection through demand planning, donor scheduling, inventory allocation, phlebotomy workflow optimization, vein visualization support, route planning for mobile drives, and automated quality checks. AI-enabled analytics can help blood centers and hospitals reduce shortages and wastage by aligning collection activity with utilization patterns, component shelf-life constraints, blood group demand, and emergency preparedness requirements.

The cumulative impact is operational rather than purely technological: faster triage, improved donor engagement, better staffing decisions, earlier detection of collection anomalies, and improved specimen integrity. Adoption must remain evidence-led, with validated algorithms, human oversight, cybersecurity controls, privacy safeguards, explainable decision logic, and bias monitoring embedded into blood service governance and laboratory quality management systems.

Key Regional Insights Across Blood Collection Markets

Asia-Pacific is shaped by large patient populations, expanding diagnostic networks, rising surgical volumes, and government-backed blood safety programs across China, India, Japan, Australia, and South Korea. National efforts to improve voluntary donation, blood screening, and laboratory accreditation are strengthening demand for reliable blood collection tubes, blood bags, safety needles, and cold-chain-compatible collection workflows. North America benefits from advanced hospital infrastructure, FDA and Health Canada oversight, mature laboratory networks, and strong adoption of safety-engineered blood collection devices, supported by established infection prevention policies and occupational safety requirements.

Latin America, led by Brazil and Mexico, is modernizing blood banking capacity while addressing uneven access across urban and rural settings, creating demand for cost-effective, compliant, and durable blood collection consumables. Europe is guided by strict quality systems, CE-marked medical technologies, ISO-aligned laboratory practices, and regional blood, tissue, and cell safety frameworks that emphasize traceability, donor protection, and product conformity. The Middle East is investing in hospital expansion, medical tourism, emergency care readiness, and centralized procurement, while Africa remains focused on WHO-aligned safe blood access, screening capacity, cold-chain reliability, rural collection coverage, and workforce training to reduce preventable transfusion risks.

Key Group Insights for Strategic Market Positioning

ASEAN markets are advancing blood collection through hospital modernization, regulatory harmonization efforts, and growing demand for diagnostic testing across Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines. These countries are strengthening blood bank operations, infection control practices, and access to quality collection consumables while balancing affordability with international standards. The GCC is emphasizing premium hospital infrastructure, national health transformation programs, emergency response capacity, and centralized purchasing that favors compliant, high-quality blood collection devices, sterile consumables, and digital traceability tools.

The European Union remains a benchmark for safety, traceability, and product conformity through harmonized medical device regulation, blood safety requirements, and strong quality management expectations. BRICS countries combine large demand pools with domestic manufacturing ambitions, public hospital expansion, and growing emphasis on supply-chain resilience for blood collection tubes, bags, needles, and plasma-related systems. G7 markets are leading in automation, digital health integration, laboratory accreditation, donor management, and occupational safety adoption. NATO countries increasingly evaluate blood collection and transfusion readiness as part of emergency preparedness, battlefield medicine, trauma response, disaster planning, and resilient medical supply chains.

Key Country Insights in Blood Collection

The United States leads through high testing volumes, FDA-regulated medical devices, large blood center networks, occupational safety standards, and rapid adoption of safety-engineered blood collection systems. Canada emphasizes coordinated national blood services, quality assurance, donor safety, and standardized transfusion practices, while Mexico and Brazil are expanding access through hospital investment, public health modernization, and improved blood bank infrastructure. The United Kingdom, Germany, France, Italy, and Spain maintain mature laboratory and transfusion systems supported by strong standards, accreditation practices, centralized procurement discipline, and sustained demand for reliable evacuated tubes, blood bags, needles, and preanalytical quality solutions.

Russia is strengthening domestic supply resilience and healthcare self-sufficiency, while China and India combine large-scale healthcare demand with expanding local manufacturing, rising diagnostic utilization, and government efforts to improve blood safety and hospital capacity. Japan and South Korea emphasize precision, automation, quality control, and laboratory efficiency in clinical diagnostics and transfusion services. Australia benefits from advanced blood service governance, robust quality systems, and geographic logistics expertise, supporting reliable collection, testing, storage, and distribution across dispersed populations and remote care settings.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize safety-engineered devices, preanalytical quality, donor and patient comfort, and compatibility with automated laboratory workflows. Product portfolios should address both high-throughput hospital environments and decentralized collection models, including capillary sampling, mobile blood donation, plasma collection, home-based sample collection, and point-of-care diagnostics.

Commercial teams should align launches with local regulatory requirements, reimbursement realities, blood service procurement cycles, laboratory accreditation needs, and workforce training requirements. Partnerships with hospitals, reference laboratories, blood centers, public health agencies, and digital health vendors can strengthen differentiation through education, traceability, inventory analytics, cold-chain visibility, and measurable reductions in sample rejection, hemolysis, contamination, and needlestick exposure.

Research Methodology

The research methodology combines secondary research from verified public health, regulatory, clinical, standards, and trade sources with structured market validation. Key references include WHO guidance on blood safety and availability, FDA medical device requirements, CDC infection prevention resources, ISO standards, CLSI guidance, national blood service publications, public procurement documents, clinical laboratory standards, and peer-reviewed literature on transfusion medicine and preanalytical quality.

Insights are triangulated across product categories, end users, procurement patterns, regional policy environments, blood safety programs, regulatory developments, and technology adoption signals. The approach emphasizes data reliability, source transparency, and practical relevance for executives evaluating blood collection devices, sterile consumables, automation, donor management systems, plasma collection workflows, and digital traceability investments.

Conclusion: Building a Safer and Smarter Blood Collection Ecosystem

Blood collection remains foundational to safe diagnosis, transfusion, plasma-derived therapies, maternal care, oncology treatment, surgery, emergency medicine, and public health surveillance. Market momentum is being shaped by safety requirements, rising testing demand, hospital modernization, donor management needs, infection prevention policies, and the transition toward connected, automated, and patient-friendly collection models.

Organizations that combine regulatory rigor, evidence-based design, supply-chain resilience, user training, and digital workflow intelligence will be best positioned to compete. The strongest opportunities will come from solutions that improve donor and patient experience while supporting reliable specimen quality, traceability, sterility, occupational safety, and timely clinical decision-making.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Blood Collection Market, by Product Type

• 7.1. Accessories
• 7.2. Lancets
• 7.3. Syringes & Needles
  • 7.3.1. Needles
    • 7.3.1.1. Safety Needles
    • 7.3.1.2. Standard Needles
  • 7.3.2. Syringes
• 7.4. Vacuum Tube Systems
  • 7.4.1. Glass Vacuum Tubes
  • 7.4.2. Plastic Vacuum Tubes

8. Blood Collection Market, by Technology

• 8.1. Closed Systems
• 8.2. Open Systems

9. Blood Collection Market, by Application

• 9.1. Blood Banking
• 9.2. Clinical Diagnostics
• 9.3. Research

10. Blood Collection Market, by End User

• 10.1. Ambulatory Care Centers
• 10.2. Diagnostic Laboratories
• 10.3. Home Care
• 10.4. Hospitals
• 10.5. Research Institutes

11. Blood Collection Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Blood Collection Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Blood Collection Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Concentration Analysis, 2025
  • 14.1.1. Concentration Ratio (CR)
  • 14.1.2. Herfindahl Hirschman Index (HHI)
• 14.2. Recent Developments & Impact Analysis, 2025
• 14.3. Product Portfolio Analysis, 2025
• 14.4. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. Abbott Laboratories
• 15.2. AdvaCare Pharma
• 15.3. Becton, Dickinson & Company
• 15.4. Biosigma S.p.A.
• 15.5. Bio-Rad Laboratories, Inc.
• 15.6. Cardinal Health, Inc.
• 15.7. CML BIOTECH LIMITED
• 15.8. Convergent Technologies GmbH
• 15.9. Corning Incorporated
• 15.10. FL Medical S.R.L.
• 15.11. Greiner Bio One International Gmbh
• 15.12. Haemonetics Corporation
• 15.13. Labtech S.r.l.
• 15.14. Medline Industries, Inc.
• 15.15. Medtronic plc
• 15.16. Merck KGaA.
• 15.17. Micsafe Medical Group
• 15.18. Nanjing Vazyme Medical Technology Co., Ltd.
• 15.19. Nipro Medical Corporation
• 15.20. QIAGEN N.V.
• 15.21. Radiometer Medical ApS
• 15.22. SARSTEDT AG & Co. KG
• 15.23. Simport, Inc.
• 15.24. Terumo Corporation
• 15.25. Thermo Fisher Scientific